FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071799294> ?p ?o ?g. }

• W2071799294 endingPage "1294" @default.
• W2071799294 startingPage "1288" @default.
• W2071799294 abstract "Data from randomized clinical trials have shown the safety and efficacy of the XIENCE V in selected populations. However, limited data are available comparing the XIENCE V to the first-generation CYPHER sirolimus-eluting stent. This study aimed to assess the long-term safety and clinical efficacy of the XIENCE V everolimus-eluting stent compared to first-generation stents in an unselected patient population. This retrospective analysis included 6,069 patients treated with CYPHER, TAXUS, and XIENCE stents from 2003 to 2009 at our institution. The patients were followed up for ≥1 year after the index procedure. The baseline characteristics were generally comparable among the 3 groups, with the exception of a significantly greater prevalence of diabetes mellitus, systemic hypertension, and a history of angioplasty and coronary bypass surgery among the XIENCE patients. The XIENCE patients also had a twofold greater rate of type C lesions. One-year follow-up data were available for 82% of the patients. The 1-year major adverse cardiovascular events rate was 9.3% for the XIENCE stent versus 9.8% for the CYPHER stent and 11.5% for the TAXUS stent (p = 0.11). Mortality was lower in the XIENCE group than in the CYPHER and TAXUS groups (3.6% vs 4.9% vs 7.2%, respectively, p <0.001), and target lesion revascularization was similar (5.9% vs 5.2% vs 5.6%, respectively; p = 0.34). Stent thrombosis was lower in the XIENCE patients (0.2% vs 1.2% vs 0.7%, p = 0.007). In conclusion, in a contemporary United States clinical practice with an unselected patient population, use of the XIENCE V stent was associated with an improved safety profile and reduction of all-cause mortality and stent thrombosis compared to first-generation drug-eluting stents. The XIENCE V failed to demonstrate superiority for overall major adverse cardiovascular events, Q-wave myocardial infarction, and revascularization rates. Data from randomized clinical trials have shown the safety and efficacy of the XIENCE V in selected populations. However, limited data are available comparing the XIENCE V to the first-generation CYPHER sirolimus-eluting stent. This study aimed to assess the long-term safety and clinical efficacy of the XIENCE V everolimus-eluting stent compared to first-generation stents in an unselected patient population. This retrospective analysis included 6,069 patients treated with CYPHER, TAXUS, and XIENCE stents from 2003 to 2009 at our institution. The patients were followed up for ≥1 year after the index procedure. The baseline characteristics were generally comparable among the 3 groups, with the exception of a significantly greater prevalence of diabetes mellitus, systemic hypertension, and a history of angioplasty and coronary bypass surgery among the XIENCE patients. The XIENCE patients also had a twofold greater rate of type C lesions. One-year follow-up data were available for 82% of the patients. The 1-year major adverse cardiovascular events rate was 9.3% for the XIENCE stent versus 9.8% for the CYPHER stent and 11.5% for the TAXUS stent (p = 0.11). Mortality was lower in the XIENCE group than in the CYPHER and TAXUS groups (3.6% vs 4.9% vs 7.2%, respectively, p <0.001), and target lesion revascularization was similar (5.9% vs 5.2% vs 5.6%, respectively; p = 0.34). Stent thrombosis was lower in the XIENCE patients (0.2% vs 1.2% vs 0.7%, p = 0.007). In conclusion, in a contemporary United States clinical practice with an unselected patient population, use of the XIENCE V stent was associated with an improved safety profile and reduction of all-cause mortality and stent thrombosis compared to first-generation drug-eluting stents. The XIENCE V failed to demonstrate superiority for overall major adverse cardiovascular events, Q-wave myocardial infarction, and revascularization rates." @default.
• W2071799294 created "2016-06-24" @default.
• W2071799294 creator A5002279235 @default.
• W2071799294 creator A5019308713 @default.
• W2071799294 creator A5023256291 @default.
• W2071799294 creator A5046457452 @default.
• W2071799294 creator A5049224966 @default.
• W2071799294 creator A5049433909 @default.
• W2071799294 creator A5061220352 @default.
• W2071799294 creator A5065906924 @default.
• W2071799294 creator A5079974007 @default.
• W2071799294 creator A5082637722 @default.
• W2071799294 creator A5083223444 @default.
• W2071799294 date "2012-05-01" @default.
• W2071799294 modified "2023-10-18" @default.
• W2071799294 title "Safety and Efficacy of the XIENCE V Everolimus-Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice" @default.
• W2071799294 cites W1718290785 @default.
• W2071799294 cites W1959538729 @default.
• W2071799294 cites W1976713371 @default.
• W2071799294 cites W2009589924 @default.
• W2071799294 cites W20404472 @default.
• W2071799294 cites W2079818105 @default.
• W2071799294 cites W2083630382 @default.
• W2071799294 cites W2089313624 @default.
• W2071799294 cites W2125716797 @default.
• W2071799294 cites W2127994240 @default.
• W2071799294 cites W2151062204 @default.
• W2071799294 cites W2165806143 @default.
• W2071799294 cites W90678752 @default.
• W2071799294 doi "https://doi.org/10.1016/j.amjcard.2011.12.019" @default.
• W2071799294 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22341925" @default.
• W2071799294 hasPublicationYear "2012" @default.
• W2071799294 type Work @default.
• W2071799294 sameAs 2071799294 @default.
• W2071799294 citedByCount "29" @default.
• W2071799294 countsByYear W20717992942012 @default.
• W2071799294 countsByYear W20717992942013 @default.
• W2071799294 countsByYear W20717992942014 @default.
• W2071799294 countsByYear W20717992942015 @default.
• W2071799294 countsByYear W20717992942016 @default.
• W2071799294 countsByYear W20717992942018 @default.
• W2071799294 countsByYear W20717992942019 @default.
• W2071799294 countsByYear W20717992942020 @default.
• W2071799294 countsByYear W20717992942021 @default.
• W2071799294 countsByYear W20717992942022 @default.
• W2071799294 countsByYear W20717992942023 @default.
• W2071799294 crossrefType "journal-article" @default.
• W2071799294 hasAuthorship W2071799294A5002279235 @default.
• W2071799294 hasAuthorship W2071799294A5019308713 @default.
• W2071799294 hasAuthorship W2071799294A5023256291 @default.
• W2071799294 hasAuthorship W2071799294A5046457452 @default.
• W2071799294 hasAuthorship W2071799294A5049224966 @default.
• W2071799294 hasAuthorship W2071799294A5049433909 @default.
• W2071799294 hasAuthorship W2071799294A5061220352 @default.
• W2071799294 hasAuthorship W2071799294A5065906924 @default.
• W2071799294 hasAuthorship W2071799294A5079974007 @default.
• W2071799294 hasAuthorship W2071799294A5082637722 @default.
• W2071799294 hasAuthorship W2071799294A5083223444 @default.
• W2071799294 hasConcept C126322002 @default.
• W2071799294 hasConcept C141071460 @default.
• W2071799294 hasConcept C164705383 @default.
• W2071799294 hasConcept C2777546689 @default.
• W2071799294 hasConcept C2778283817 @default.
• W2071799294 hasConcept C2778583881 @default.
• W2071799294 hasConcept C2779699572 @default.
• W2071799294 hasConcept C2780326628 @default.
• W2071799294 hasConcept C2908647359 @default.
• W2071799294 hasConcept C71924100 @default.
• W2071799294 hasConcept C99454951 @default.
• W2071799294 hasConceptScore W2071799294C126322002 @default.
• W2071799294 hasConceptScore W2071799294C141071460 @default.
• W2071799294 hasConceptScore W2071799294C164705383 @default.
• W2071799294 hasConceptScore W2071799294C2777546689 @default.
• W2071799294 hasConceptScore W2071799294C2778283817 @default.
• W2071799294 hasConceptScore W2071799294C2778583881 @default.
• W2071799294 hasConceptScore W2071799294C2779699572 @default.
• W2071799294 hasConceptScore W2071799294C2780326628 @default.
• W2071799294 hasConceptScore W2071799294C2908647359 @default.
• W2071799294 hasConceptScore W2071799294C71924100 @default.
• W2071799294 hasConceptScore W2071799294C99454951 @default.
• W2071799294 hasIssue "9" @default.
• W2071799294 hasLocation W20717992941 @default.
• W2071799294 hasLocation W20717992942 @default.
• W2071799294 hasOpenAccess W2071799294 @default.
• W2071799294 hasPrimaryLocation W20717992941 @default.
• W2071799294 hasRelatedWork W1524803505 @default.
• W2071799294 hasRelatedWork W2009328296 @default.
• W2071799294 hasRelatedWork W2074384350 @default.
• W2071799294 hasRelatedWork W2077200312 @default.
• W2071799294 hasRelatedWork W2131308249 @default.
• W2071799294 hasRelatedWork W2156495621 @default.
• W2071799294 hasRelatedWork W2315179892 @default.
• W2071799294 hasRelatedWork W2382588851 @default.
• W2071799294 hasRelatedWork W90311969 @default.
• W2071799294 hasRelatedWork W2488355316 @default.
• W2071799294 hasVolume "109" @default.
• W2071799294 isParatext "false" @default.
• W2071799294 isRetracted "false" @default.

• next